ADMA ADMA Corp: רווח נקי למניה ב-12 החודשים האחרונים

ADMA Biologics dominates the plasma-replacement segment through patents and raw material shortages. Its own facility in Florida guarantees supply stability. The annual percentage change in EPS TTM confirms the model's efficiency, where -10.70 shows the value of this parameter. Growth is supported by strategic partnerships with blood collection centers and joint research with immunological institutes.

High barriers to entry in the plasma replacement sector, driven by stringent FDA oversight, provide ADMA Biologics (ADMA) with a sustainable competitive advantage. By analyzing the YoY TTM change in net income per share, an investor assesses the business's ability to scale revenue faster than cost inflation, where outperforming industry-average growth rates confirms efficient capital management and the high market value of protected assets.